Episode Description from the Publisher
Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" pathway. I could see folks being excited for this, especially in a disease where non-scary-manifestations are relatively common. Also, check out boardsbank.com! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2601337
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Get Free Summaries →
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
Get summaries like this every morning.
Free AI-powered recaps of The Evidence Based Rheumatology Podcast and your other favorite podcasts, delivered to your inbox.
Get Free Summaries →
Free forever for up to 3 podcasts. No credit card required.